Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Rifampicin is a potent inducer of the CYP450 and decrease the plasmatic concentration of
NNRTI and Protease Inhibitors. In our study we are going to compare the 600 an 800mg doses of
efavirenz concomitant of rifampicin use to treat tuberculosis. The hypothesis is that the 800
mg dose would be more adequate than the 600mg